Date: 2014-10-16
Type of information: Capital increase
Company: Epigenomics (Germany - USA - MD
Investors: BioChain Institute (USA - CA)
Amount: $ 5.3 million (€ 4.2 million)
Funding type: capital increase
Planned used: Epigenomics AG intends to use the net proceeds from the capital increase to finance its current operations and to strengthen the distribution capabilities for its lead product Epi proColon®, a convenient blood-based test for the early detection of colorectal cancer. These funds will extend Epigenomics\' cash for the final steps in the approval of Epi proColon® in the US and in China.
Others: * On October 16, 2014, Epigenomics, the German-American cancer molecular diagnostics company, announced that the Company is raising $ 5.3 million (€ 4.2 million) in a share capital increase. BioChain Institute will subscribe a total of 1,351,089 Epigenomics shares which will be issued under exclusion of the statutory subscription right of the shareholders. The Executive Board of Epigenomics AG, with approval of the Supervisory Board, resolved on the increase of the of the Company\'s share capital by the amount of €1,351,089 by issuance of 1,351,089 new shares from the Authorized Capital 2014/I against contribution in cash. The issue price has been set at €3.08 per share, based on the XETRA closing price of the day prior to the announcement, Wednesday, October 15, 2014. After registration of the capital increase on or around November 21, 2014, the subscribed capital of Epigenomics AG will increase from currently €13,517,558 to € 14,868,647.
Therapeutic area: Cancer - Oncology - Diagnostic
